
Scinai Immunotherapeutics
The leading #UniversalFluVaccine candidate: Designed for multi-season multi-strain protection from seasonal & pandemic influenza; Phase 3 trial. (NASDAQ: $BVXV).
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
* | $10.0m | Post IPO Equity | |
Total Funding | 000k |




ILS | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is an Israeli biopharmaceutical company executing a strategic pivot with a dual-focus business model. The firm combines the development of an in-house pipeline of inflammation and immunology (I&I) therapeutics with the operation of a boutique Contract Development and Manufacturing Organization (CDMO) under the brand Scinai Bioservices. This structure aims to generate near-term revenue to support its long-term, capital-intensive research and development efforts.
Originally founded as BiondVax Pharmaceuticals in 2003 and publicly traded since 2015, the company rebranded to Scinai Immunotherapeutics in September 2023. This change followed the appointment of CEO Amir Reichman in March 2021 and marked a strategic shift away from its prior focus on a universal flu vaccine towards novel I&I biologics and CDMO services. Reichman, an Israeli native, brought extensive experience from senior roles at GSK and Novartis Vaccines. His academic work previously contributed to the founding of NeuroDerm, which was later acquired for $1.1 billion.
The company's therapeutic pipeline is centered on nanosized VHH antibodies, also known as NanoAbs, which are derived from alpacas. These NanoAbs are being developed in collaboration with Germany's Max Planck Institute and University Medical Center Göttingen. The NanoAb platform offers advantages over traditional monoclonal antibodies, including higher stability, more convenient administration routes, and lower production costs. Scinai's pipeline targets diseases with significant unmet needs, such as psoriasis, psoriatic arthritis, and asthma. Additionally, Scinai is expanding its pipeline through the potential acquisition of Pincell S.r.l., an Italian biotech, to gain its monoclonal antibody asset, PC111, for treating severe dermatological conditions.
Scinai's business model relies on two revenue streams. The Scinai Bioservices CDMO unit, launched in 2024, provides end-to-end services, including process development, cGMP manufacturing, and analytical services, to other early-stage biotech companies. This unit operates from a 20,000-square-foot, EMA and FDA-compliant facility in Jerusalem and began generating its first revenues in 2024. For the first quarter of 2025, the CDMO business reported revenues of $586,000. The second stream is the long-term commercialization of its proprietary NanoAb therapies through licensing fees, milestone payments, and royalties.
Keywords: Scinai Immunotherapeutics, biopharmaceutical, CDMO services, inflammation and immunology, NanoAbs, VHH antibodies, autoimmune diseases, psoriasis treatment, asthma therapy, contract manufacturing, biologics development, Amir Reichman, Max Planck Institute, Pincell, PC111, monoclonal antibody, drug development, cGMP manufacturing, Scinai Bioservices, nanobodies, alpaca-derived antibodies, biopharma, therapeutic pipeline
Tech stack
Investments by Scinai Immunotherapeutics
Edit